Q1 EPS Forecast for Pacira BioSciences Lowered by Analyst

On December 11, 2024, Zacks Research announced a downward revision of its earnings estimates for Pacira BioSciences, Inc. (NASDAQ:PCRX). The investment firm now predicts that Pacira will report earnings of $0.60 per share for the first quarter of 2025, which is a slight decrease from the previous estimate of $0.61 per share. In addition, the consensus estimate for the company's total earnings for the current fiscal year stands at $2.28 per share.

In their report, Zacks also provided forecasts for future earnings, estimating that Pacira will earn $0.54 per share in the third quarter of 2025 and $0.63 per share in the second quarter of 2026.

Several other analysts have recently shared their views on Pacira BioSciences. For instance, Royal Bank of Canada raised its price target for the stock from $15.00 to $16.00 and gave it a “sector perform” rating on November 7. Jefferies Financial Group also increased their price target from $15.00 to $18.00, labeling the stock as a “buy” in a report released on September 24. On December 4, HC Wainwright reiterated a “buy” rating and set a price target of $39.00. Conversely, Barclays reduced their price objective from $25.00 to $17.00 and designated the stock as “equal weight” on November 12. Needham & Company LLC reaffirmed a “buy” rating with a price target of $22.00 on November 8.

Overall, the analyst ratings for Pacira BioSciences show a mix of opinions, with two analysts recommending a sell rating, four suggesting a hold, and five advocating for a buy rating. According to MarketBeat data, the average analyst rating for Pacira BioSciences is currently “Hold,” with a consensus target price of $23.50.

Analysis of Pacira BioSciences Stock Performance

As of the latest trading session, Pacira BioSciences' stock opened at $19.86. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25, and a quick ratio of 1.89. Its fifty-day moving average price stands at $17.27, while the 200-day moving average price is $19.12. Over the past year, the stock has experienced a low of $11.16 and a high of $35.95. The company holds a market capitalization of $916.94 million and has a price-to-earnings ratio of -9.78, with a beta value of 0.80.

Institutional Investment Activities

Recently, several hedge funds and institutional investors have adjusted their stakes in Pacira BioSciences. For example, Innealta Capital LLC purchased a new position in the company during the second quarter, with an investment valued at around $50,000. nVerses Capital LLC significantly increased its ownership by 800% during the same quarter. They now hold 1,800 shares, valued at approximately $51,000, after acquiring an additional 1,600 shares. CWM LLC also raised its position by 713.6% in the third quarter, now owning 6,517 shares worth $98,000 after buying 5,716 more shares. Other institutional buyers included Virtus Investment Advisers Inc. and Quest Partners LLC, both of which made new investments in the stock during the quarter. Notably, hedge funds and institutional investors collectively hold approximately 99.73% of Pacira's stock.

About Pacira BioSciences

Pacira BioSciences, Inc. is a company dedicated to the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions in the United States. Its product portfolio includes EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide; and the iovera system, a non-opioid handheld cryoanalgesia device designed for delivering controlled doses of cold to targeted nerves.

Conclusion

With a notable reassessment of the Q1 earnings expectations, analysts remain cautious, while institutional interest continues to shape the investment landscape of Pacira BioSciences. Investors will be keenly watching for future developments as the company aims for growth in the competitive offerings of pain management solutions.

Pacira, Earnings, Analyst